Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063482 | 0.88 | SCN9A (0.44) | SCN9ACHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL20063485 | 0.82 | SCN9A (0.46) | SCN9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20095914 | 0.79 | CHRNB2 (0.44) | SCN9ACHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL20063440 | 0.78 | PIM1 (0.33) | — | |
| SCHEMBL24260145 | 0.75 | TAS1R3 (0.34) | DPP4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20063436 | 0.74 | SCN9A (0.35) | SCN9A | |
| SCHEMBL20072753 | 0.73 | SCN9A (0.33) | SCN9ADPP4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24260113 | 0.73 | SCN9A (0.33) | SCN9ADPP4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20063442 | 0.72 | SCN9A (0.41) | SCN9A | |
| SCHEMBL20063404 | 0.72 | PIM1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1478/4885CHRNB2 3015/4885CHRNA3 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.